Answers are grounded in this paper and cite their sources.
BACKGROUND: Cognitive impairment in schizophrenia-spectrum disorders is highly prevalent and notably influences functional outcomes. AIMS: To characterise the cognitive effectiveness of second-generation antipsychotic drugs. METHOD: One hundred consecutive and previously unmedicated patients with first-episode schizophrenia-spectrum disorders were admitted. Seventy-seven completed baseline, 1-month and 6-month psychopathological and neuropsychological assessments. Patients were randomised to risperidone or olanzapine treatment. Four final treatment allocation groups were defined since patients continued treatment in their normal setting: risperidone, olanzapine, mixed and no-antipsychotic groups. RESULTS: There were no differences in cognitive effectiveness between the four treatment groups. Reliable change index methods demonstrated that nearly a half of patients showed an improvement in Global Cognitive Score at the 6-month assessment. Improvement on the neuropsychological tests ranged from 17 to 54%. A strong predictor of cognitive response was poor performance on baseline neuropsychological tests; response was moderately influenced by a low premorbid scholastic performance and IQ. CONCLUSIONS: Cognitive improvement related to second-generation antipsychotic drugs appeared within the first 4 weeks of treatment and persisted at 6 months irrespective of treatment group. Greater cognitive dysfunction at baseline and lower premorbid cognitive background predicted cognitive improvement in our sample.
No takes yet. Share an insight, caveat, or question.
Cuesta et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: